Biogen's (BIIB) Anti-LINGO Data Better then Expected; Stifel Affirms at 'Hold'
- Wall Street drops as investors brace for presidential debate
- Disney (DIS) Working with Adviser on Potential Twitter (TWTR) Bid - Bloomberg
- Rice Energy (RICE) Acquires Vantage Energy in $2.7B Deal; FY16 Outlook Updated
- CBOE Holdings (CBOE) to Acquire Bats Global Markets (BATS) in ~$3.2B Deal
- LANXESS to Acquire Chemtura (CHMT) in ~$2.5B Deal
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Stifel affirms Biogen (Nasdaq: BIIB) at Hold following the release of Anti-LINGO data.
The firm commented:
Biogen finally released a sea of molecular and subgroup data from the SYNERGY trial. We find the detailed data much more encouraging that the Company’s original topline release and to our eyes responder analyses strongly suggest activity in the 10mg/kg and 30mg/kg subgroups. Other interesting features of the data include the poor efficacy of the highest dose group – consistent with meaningful brain penetration and better responses in all the expected groups including RRMS over SPMS and low numbers of brain lesions. Finally a correlation between patients that improved and some imaging endpoints suggests the company now has an assay (analogues to PET-imaging of A-beta plaque) to enrich further trials. The muted stock reaction suggests investors are looking at these data through a very different lens than was used for drugs like Solanezumab. MS is a degenerative disease; improvement in any patient group resulting from any duration of treatment could be very valuable.
Do we have a Subgroup? Detailed analysis of the SYNERGY study suggests that the least impacted subpopulation showed the most benefit from the treatment – a result that seems completely expected. For example, patients who at baseline had a “DTI score” of less than 0.73x10-3 showed the greatest clinical benefit on the primary endpoint, with an odds ratio of 6.35 (CI 2.43-16.62, p-value=0.0002) (Exhibit 1, DTI is an imaging parameter related to tissue integrity). Perhaps more importantly, this same parameter was seen to improve in patients marked as responders based on clinical improvements. As a result, Biogen seems to have an imaging biomarker it can use to enrich subsequent trials. This ability has been extremely valuable in the development of its AD antibody Aducanumab.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), Ionis (IONS) Announce Completion of Nusinersen NDA Rolling Submission as SMA Treatment
- Stifel Reiterates Buy on Kraft Heinz (KHC) After Adjusting Estimates
- Marriott (MAR): Key Merger Points - Stifel
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!